(redirected from DPP-4 inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: deterrent
References in periodicals archive ?
Since the Food and Drug Administration (FDA) approved the use of dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of diabetes in 2006, the latest guidelines of ADA, AACE and NICE involve the DPP-4 inhibitors for the treatment of type 2 DM.
Key clinical point: Neither GLP-l receptor agonists nor DPP-4 inhibitors increase the risk of acute pancreatitis in type 2 diabetes patients.
DPP-4 inhibitors work by increasing hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose.
The median time to treatment discontinuation was 90 days in the GLP- 1 agonist cohort, 120 days for the DPP-4 inhibitor cohort, and 90 days for patients assigned to other antidiabetic agents.
In addition, the NICE guideline recognises the role of sitagliptin as the only DPP-4 inhibitor licensed for use in triple therapy with metformin and an SU where metformin and an SU do not adequately control blood sugar (HbA1c greater than or equal to 7.
The same patient that you would think of using pioglitazone for is probably an ideal candidate for a combination of pioglitazone and a DPP-4 inhibitor like alogliptin," said Dr.
Nineteen DPP-4 inhibitor trials involved sitagliptin, 10 involved saxagliptin, 7 vildagliptin, and 6 alogliptin.
Pinoxacin Hydrochloride is DPP-4 inhibitor class of oral hypoglycemic agents, a drug with a brand new structure for treating type II diabetes.
but] a DPP-4 inhibitor is not going to get your patient to goal unless their [Hb][A.
Alogliptin is a dipeptidyl peptidase IV or DPP-4 inhibitor being investigated as an adjunct to diet and exercise for the treatment of Type 2 diabetes.
Linagliptin is currently the only DPP-4 inhibitor that is being compared to a sulfonylurea in a long-term cardiovascular (CV) outcome study.